Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Metsera Inc. (MTSR : NSDQ)

• Company Description    Metsera Inc. is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight and related conditions. Metsera Inc. is based in NEW YORK. Number of Employees: 81

• Price / Volume Information    Yesterday's Closing Price: $83.18 Daily Weekly Monthly 20 Day Moving Average: 2,835,356 shares Shares Outstanding: 105.29 (millions) Market Capitalization: $8,758.25 (millions) Beta: 52 Week High: $83.86 52 Week Low: $12.30 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 57.33% 53.21% 12 Week 167.12% 156.04% Year To Date % %

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3 WORLD TRADE CENTER 175 GREENWICH STREET - NEW YORK,NY 10007 USA ph: 212-784-6595 fax: - investors@metsera.com http://www.metsera.com

• General Corporate Information    Officers Christopher Whitten Bernard - Chief Executive Officer;President and Director Clive A. Meanwell - Executive Chairman of the Board of Directors Christopher J. Visioli - Chief Financial Officer and Chief Business Officer Paul L. Berns - Director Kristina M. Burow - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 59267L107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/10/25 Share - Related Items Shares Outstanding: 105.29 Most Recent Split Date: (:1) Beta: Market Capitalization: $8,758.25 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.00 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.79 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/10/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 19.45 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: 35.92% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - - 03/31/25 - - ROA 09/30/25 - - 06/30/25 - - 03/31/25 - - Current Ratio 09/30/25 - - 06/30/25 - 5.26 03/31/25 - 6.55 Quick Ratio 09/30/25 - - 06/30/25 - 5.26 03/31/25 - 6.55 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 4.28 03/31/25 - 4.82 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©